Specialized Investment Fund distribution now requires dedicated certification, while transitional recognition preserves existing qualified distributor...
Overlapping GST proceedings require Central and State authorities to designate one competent authority for coordinated adjudication of the same matter...
Composite healthcare supplies retain exemption when patient care is the contract's essential character, despite payment through an implementing agency...
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.